2022-05-16T17:31:17-05:00 2021-06-30 814234542 BPM LLP 4200 BOHANNON DRIVE SUITE 250 MENLO PARK CA 940251021 990 2020-07-01 453266802 CANCER COMMONS CANC 6502894044 650 CASTRO STREET SUITE 120 PMB52 MOUNTAIN VIEW CA 94041 SHELLEY FRISBIE CHIEF FINANCIAL OFFICER 6502894044 2022-05-13 1 SHELLEY FRISBIE 999009999 TAMARA L MCINERNEY P00011797 6508556800 2022-05-13 2 AAL1 IAL1 2020 2022-09-23 18:48:47Z JAY M TENENBAUM 650 CASTRO STREET SUITE 120 PMB522 MOUNTAIN VIEW CA 94041 1739545 0 X WWW.CANCERCOMMONS.ORG X 2011 CA CANCER COMMONS BRINGS TOGETHER A TEAM OF EXPERTS, WHO COMBINE COMPASSION WITH SCIENTIFIC KNOWLEDGE TO HELP PATIENTS UNDERSTAND THEIR DISEASE AND ACCESS THEIR BEST TREATMENT OPTIONS. EACH PATIENT IS CONNECTED TO A TEAM, CONSISTING OF NURSE NAVIGATORS, PHD SCIENTISTS, PHYSICIANS, AND NATIONAL EXPERTS, WHO, REVIEW THE PATIENT'S MEDICAL HISTORY, RESEARCH ADDITIONAL TESTING THAT COULD IMPACT THE PATIENT'S TREATMENT PLAN, IDENTIFY CLINICAL TRIAL OPTIONS AVAILABLE FOR THE PATIENT, INVESTIGATE ACCESS TO NEW OFF-LABEL TREATMENTS, AS WELL AS OBTAIN KEY INSIGHTS FROM CANCER EXPERTS THROUGH VIRTUAL TUMOR BOARDS. CANCER COMMONS' GOAL IS TO EQUIP PATIENTS WITH THE KNOWLEDGE THEY NEED TO BE ABLE TO CHOOSE THEIR BEST PLAN OF ACTION AT NO COST TO THE PATIENT. 6 5 10 2 0 0 2103518 1733265 0 0 0 0 868 6280 2104386 1739545 0 0 0 0 1109381 1157737 0 0 169178 820505 540278 1929886 1698015 174500 41530 883100 829247 173708 78325 709392 750922 X CANCER COMMONS BRINGS TOGETHER A TEAM OF EXPERTS, WHO COMBINE COMPASSION WITH SCIENTIFIC KNOWLEDGE TO HELP PATIENTS UNDERSTAND THEIR DISEASE AND ACCESS THEIR BEST TREATMENT OPTIONS. 0 0 1352332 6280 SEE SCHEDULE O 1352332 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 20 0 10 1 0 0 0 0 0 0 0 0 0 0 0 0 X 6 5 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 CA X MARTHA DEHNOW 6505303636 650 CASTRO STREET SUITE 120 PMB522 MOUNTAIN VIEW CA 94041 X JAY M TENENBAUM CHAIR, DIRECTOR, PRESIDENT 20.00 X X 0 0 0 LAURENCE MARTON DIRECTOR 0.25 X 0 0 0 GLADYS MONROY DIRECTOR 0.25 X 0 0 0 EDWARD STAREN DIRECTOR 0.25 X 0 0 0 VERN NORVIEL DIRECTOR 0.25 X 0 0 0 MARK JACOBSTEIN DIRECTOR 0.25 X 0 0 0 SHELLEY FRISBIE CFO 18.00 X 101875 0 0 MASAKO YOKOTA SECRETARY 0.25 X 0 0 0 ERIKA MONTEVERDI EXECUTIVE DIRECTOR 40.00 X 213993 0 30617 LESLIE JARED NURSE NAVIGATOR 40.00 X 120567 0 1177 EMILYA SHTIVELMAN CHIEF SCIENTIST 33.00 X 128510 0 22294 LOLA RAHIB SCIENTIST 40.00 X 139783 0 9899 MATTHEW WARNER SCIENTIST 40.00 X 113952 0 317 818680 0 64304 6 0 1 0 THE SHELLARD GROUP 1325 HOWARD AVE 944 BURLINGAME CA 94010 GENERAL & ADMINISTRATION, ACCOUNTING 101875 PATRICK VAN DER VALK RUA JOAO LUIS RICARDO 65-4B PAREDE PO 2775-211 MARKETING 101875 2 194980 1538285 1733265 MISCELLANEOUS INCOME 900099 6280 6280 6280 1739545 6280 0 0 X 360465 235515 87559 37391 654388 580584 25848 47956 80741 47898 21566 11277 62143 56581 1854 3708 6997 5254 1743 32754 9826 11464 11464 435003 369019 20346 45638 27427 15462 1601 10364 1411 1274 137 1822 1822 OTHER EXPENSES 34864 30919 2565 1380 1698015 1352332 176505 169178 657483 666211 187500 134000 1278 32590 24053 8612 6907 3527 1705 2000 2000 883100 829247 168528 78325 5180 0 173708 78325 X 546140 650922 163252 100000 709392 750922 883100 829247 41530 0 X X 0 1 X 1 0 X 1410505 1622936 1802396 2103518 1733265 8672620 1410505 1622936 1802396 2103518 1733265 8672620 4612329 4060291 2500 868 6329 9697 8682317 0.46770 0.42900 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 8612 6907 1705 1705 X 1739545 0 1739545 0 1739545 1698015 0 1698015 0 1698015 PART X, LINE 2: ACCOUNTING PRINCIPLES GENERALLY ACCEPTED IN THE UNITED STATES OF AMERICA PROVIDE ACCOUNTING AND DISCLOSURE GUIDANCE ABOUT POSITIONS TAKEN BY AN ORGANIZATION IN ITS TAX RETURNS THAT MIGHT BE UNCERTAIN. MANAGEMENT HAS CONSIDERED ITS TAX POSITIONS AND BELIEVES THAT ALL OF THE POSITIONS TAKEN BY THE ORGANIZATION IN ITS FEDERAL AND STATE EXEMPT ORGANIZATION TAX RETURNS ARE MORE-LIKELY-THAN-NOT TO BE SUSTAINED UPON EXAMINATION. EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 PROGRAM SERVICES PROGRAM SERVICES & GENERAL MARKETING 75308 0 0 0 0 0 0 75308 0 75308 0 0 0 0 0 0 PART III ACCOUNTING METHOD: X 0 0 0 0 0 0 0 0 0 ERIKA MONTEVERDI EXECUTIVE DIRECTOR 213993 0 0 0 0 0 0 0 30617 0 244610 0 0 0 EMILYA SHTIVELMAN CHIEF SCIENTIST 128510 0 0 0 0 0 0 0 22294 0 150804 0 0 0 FORM 990, PART III, LINE 4A CANCER COMMONS BRINGS TOGETHER A TEAM OF NURSE NAVIGATOR, PHD SCIENTISTS, PHYSICIANS, AND NATIONAL EXPERTS, WHO COMBINE COMPASSION WITH DEEP SCIENTIFIC KNOWLEDGE TO HELP PATIENTS UNDERSTAND THEIR DISEASE AND ACCESS THEIR BEST TREATMENT OPTIONS. CANCER TYPES - CANCER COMMONS ASSISTS PATIENTS WITH VARIOUS CANCER TYPES, PARTICULARLY THOSE THAT ARE DIFFICULT TO TREAT. THESE INCLUDE, BUT ARE NOT LIMITED TO, BRAIN, PANCREATIC, OVARIAN, COLORECTAL, BREAST, LUNG, AND BLADDAR CANCERS. ACCOMPLISHMENTS ACROSS ALL CANCER TYPES INCLUDE: FURTHER ENHANCEMENT OF THE REGISTRATION PROCESS WHICH INCLUDES A NURSE NAVIGATOR TO ASSIST PATIENTS AND CAREGIVERS COLLECT MEDICAL RECORDS AND IDENTIFY THEIR SPECIFIC NEEDS INCLUDING GOALS OF TREATMENT. INCREASED THE LIBRARY OF TREATMENT OPTIONS FOR CANCER PATIENTS, BY CANCER TYPE, BASED ON THE LATEST CLINICAL AND SCIENTIFIC DISCOVERIES. EXPANDED THE VIRTUAL TUMOR BOARDS ("VTB") PROGRAM TO INCLUDE PANCREATIC AS WELL AS BRAIN PATIENTS. VTB IS A NETWORK OF NATIONAL EXPERTS INCLUDING ONCOLOGISTS, RADIATION ONCOLOGISTS, SURGEONS, AND CLINICAL SCIENTISTS, ORGANIZED BY CANCER TYPES. THESE VTBS REVIEW INDIVIDUAL CANCER PATIENTS' CASES AND PROVIDE BEST-IN-CLASS, DETAILED TREATMENT OPTIONS REPORTS TO SHARE WITH THE PATIENTS' ONCOLOGISTS AND MEDICAL TEAMS. A NEWLY REVISED BRAND AND WEBSITE PLATFORM LAUNCED ON JULY 31, 2021, WHICH HELPED SUPPORT THE TREMENDOUS INFLUX OF NEW PATIENTS (74.5% INCREASE IN NEW PATIENTS OVER PREVIOUS FISCAL YEAR). CONTINUED POSTING AND PUBLISHING OF AN EDUCATIONAL SERIES OF ARTICLES TO INFORM PATIENTS OF THE LATEST ADVANCEMENTS IN THE FIRST OF PRECISION TECHNOLOGY. PARTNERSHIP WITH XCURES - PATIENTS ARE INVITED TO ENROLL IN A "PERPETUAL CLINICAL TRIAL" THAT CANCER COMMONS IS RUNNING IN PARTNERSHIP WITH TECHNOLOGY PARTNER XCURES. THIS PERPETUAL TRIAL IS OPEN TO PATIENTS RECEIVING CARE IN THE U.S., WHICH ALLOWS THE ORGANIZATION TO LEARN FROM EACH PATIENT TO HELP SIMILAR PATIENTS, AND EVENTUALLY, ALL FUTURE PATIENTS. XCURES CURRENTLY HAS 1,168 PATIENTS ENROLLED IN THE PROJECT, OF WHICH 716 WERE ADDED DURING THE YEAR ENDED JUNE 30, 2021. OTHER PARTNERSHIPS - CANCER COMMONS HAS PARTNERSHIPS WITH OTHER ORGANIZATION AND INSTITUTIONS WHO SHARE THE CANCER COMMONS PATIENT-CENTRIC PHILOSOPHY. THESE ORGANIZATIONS REFER PATIENTS WITH CHALLENGING CASES OR OFFER THEIR SERVICES TO CANCER COMMONS' PATIENTS. THE MOST ACTIVE PARTNERS ARE THE PANCREATIC CANCER ACTION NETWORK (PANCAN) AND THE MUSELLA FOUNDATION FOR BRAIN TUMOR RESEARCH & INFORMATION. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 IS GIVEN TO THE GOVERNING BODY BEFORE THE RETURN IS FILED. THEY REVIEW AND CAN REQUEST CHANGES AT THIS TIME. FORM 990, PART VI, SECTION B, LINE 12C THE OFFICERS, DIRECTORS AND KEY EMPLOYEES ARE REQUIRED TO REVIEW AND SIGN THE WRITTEN CONFLICT OF INTEREST POLICY ANNUALLY. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD OF DIRECTORS PERFORMS ALL INTERVIEWS SPECIFIC TO TOP KEY POSITIONS WHICH IS THEN FORWARDED TO THE FULL BOARD OF DIRECTORS FOR REVIEW AND APPROVAL. FORM 990, PART VI, SECTION C, LINE 19 MADE AVAILABLE UPON REQUEST. FORM 990, PART VII, SECTION A, LINE 1A: SHELLEY FRISBIE'S COMPENSATION STATED ON PART VII, SECTION A, LINE 1A WAS ALSO INCLUDED AS A PAYMENT TO AN INDEPENDENT CONTRACTOR ON PART VII, PART B, LINE 1. FORM 990, PART IX, LINE 11G CONSULTING FEES: PROGRAM SERVICE EXPENSES 229,721. MANAGEMENT AND GENERAL EXPENSES 20,346. FUNDRAISING EXPENSES 45,638. TOTAL EXPENSES 295,705. MARKETING: PROGRAM SERVICE EXPENSES 139,298. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 139,298. FORM 990, PART XII, LINE 2C THE PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.